Cephalosporin Market Report
Global Cephalosporin Market is segmented By Generation (First-Generation, Second-Generation, Third-Generation, Fourth-Generation, Fifth-Generation), By End-Use (Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection, Urinary Tract Infection, Others), By Type (Branded, Generic), By Route of Administration (Intravenous, Oral), and Region - COVID-19 Impact Analysis and Forecast to 2026 This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global cephalosporin market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Global Cephalosporin Market is segmented By Generation (First-Generation, Second-Generation, Third-Generation, Fourth-Generation, Fifth-Generation), By End-Use (Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection, Urinary Tract Infection, Others), By Type...
The Global Cephalosporin Market is projected to grow from USD 13.89 billion in 2020 to USD 16.35 billion by 2026 at a CAGR of over 2.8% during the forecast period.
Figure: Global Cephalosporin Market Size, 2020-2026 (USD Billion)
Want to know the full scope of the report? Register Here
Cephalosporin is a bactericidal and β-lactam antibiotic mainly derived from the fungus Acremonium that is used to treat bactericidal infections such as skin infections, pneumonia, tonsillitis, strep throat, gonorrhoea, staph infections, and bronchitis among others. It inhibits enzymes in the cell wall of the susceptible bacteria and disrupts the cell synthesis. Cephalosporin is majorly designated for prophylaxis as well as for the treatment of infections caused by bacteria
Key players operating in the global cephalosporin market are-
The growing prevalence of infectious diseases and the increase in funding for the development of antibiotics are some of the key factors bolstering the product demand. Additionally, the surge in R&D activities for the production of combination drugs and the rising demand for antibacterial further augment the market growth. Moreover, the discovery of innovative prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant infections are likely to provide lucrative opportunities to the industry participants. However, the side effects of cephalosporin are likely to hinder the industry expansion.
By type, the cephalosporin market has been segmented into branded and generic.
By region, the Asia Pacific market witnessed the highest market share in 2020 and is estimated to grow at a substantial CAGR during the assessment period.
The outbreak of the COVID-19 virus has considerably affected the cephalosporin industry. Cephalosporin has not been proven highly effective against viruses. β-lactam antibiotics such as cephalosporin possess a bacteriostatic effect. The bacteriostatic action results in the action of subduing the growth of bacteria. β-lactam antibiotics act by preventing peptidoglycan synthase, which is an enzyme necessary for the growth of bacterial cell walls. However, cephalosporin can help to obstruct SARS-CoV-2 but have a minor impact on the market growth.
Want to know segmentation details? Register Here
The following is a list of the customers that the Cephalosporin market aims to convert the most:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The cephalosporin market is expected to grow at an impressive CAGR of 2.8% in the foreseeable future.
Aristo Pharmaceuticals Ltd (India), Baxter International (The U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (UK), Lupin Pharmaceuticals Inc. (India), Macleods Pharmaceuticals Ltd (India), Mankind Pharma (India), Merck & Co. Inc. (The U.S.), Pfizer Inc. (The U.S.), and Teva Pharmaceutical Industries Ltd. (Israel) are among the key players in the cephalosporin market.
The cephalosporin market size is expected to reach USD 16.35 billion in the coming years.
Asia Pacific market witnessed the highest market share in 2020 and is estimated to grow at a substantial CAGR during the assessment period.
The generic segment is expected to register the fastest CAGR in the cephalosporin market in the coming five years.
The growing prevalence of infectious diseases and the increase in funding for the development of antibiotics are some of the key factors bolstering the demand for cephalosporin.
Cephalosporin companies, Cephalosporin vendors, R&D companies, Hospitals, Drug manufacturing companies are the target audience in the cephalosporin market.